Skip to Main Content

Paper Details

MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma.
Sci Transl Med
87
2018
ERK, ERK2, IGF1R, MAPK, MEK, MYOG, MYOG locus, MYOG promoter, PAX3, PAX3/, PAX7, PAX7 fusion-negative rhabdomyosarcoma, RAF, RAS, RAS isoforms, RAS-driven rhabdomyosarcoma, RAS-mutated rhabdomyosarcoma, RMS, RNA polymerase II, cancers, chromatin, human, mitogen-activated protein kinase (MAPK) kinase, mutant RAS, oncogenic RAS, rhabdomyosarcoma, rhabdomyosarcoma cell, skeletal, skeletal muscle progenitor cells, super-enhancers, trametinib, tumor
Author NameAffiliation
Jack F ShernNational Cancer Institute
Young K SongNational Cancer Institute, National Institutes of Health (NIH)
Young K SongNational Cancer Institute, National Institutes of Health (NIH)
Arnulfo MendozaNational Cancer Institute
Arnulfo MendozaNational Cancer Institute
Xiaohu ZhangDivision of Preclinical Innovation, National Center for Advancing Translational Sciences
Rajarshi GuhaDivision of Preclinical Innovation, National Center for Advancing Translational Sciences
Rajarshi GuhaDivision of Preclinical Innovation, National Center for Advancing Translational Sciences
Jun S WeiNational Cancer Institute, National Institutes of Health (NIH)
Jun S WeiNational Cancer Institute, National Institutes of Health (NIH)
Marc FerrerDivision of Preclinical Innovation, National Center for Advancing Translational Sciences
Craig J ThomasDivision of Preclinical Innovation, National Center for Advancing Translational Sciences
Javed KhanNational Cancer Institute, National Institutes of Health (NIH)
Javed KhanNational Cancer Institute, National Institutes of Health (NIH)
  • 1 - 14

Datasets

Release 1.2